Regeneron Pharmaceuticals Inc. (REGN)’s Financial Results Comparing With Infinity Pharmaceuticals Inc. (NASDAQ:INFI)

Both Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Infinity Pharmaceuticals Inc. (NASDAQ:INFI) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Regeneron Pharmaceuticals Inc. 6.71B 6.09 2.44B 20.71 20.95
Infinity Pharmaceuticals Inc. 22.15M 4.18 11.25M 1.25 1.28

Table 1 demonstrates Regeneron Pharmaceuticals Inc. and Infinity Pharmaceuticals Inc.’s top-line revenue, earnings per share (EPS) and valuation. Infinity Pharmaceuticals Inc. appears to has lower revenue and earnings than Regeneron Pharmaceuticals Inc. Presently more expensive of the two stocks is the company with a higher price-to-earnings ratio. Regeneron Pharmaceuticals Inc.’s shares have been trading at higher price-to-earnings ratio which means it is presently more expensive than Infinity Pharmaceuticals Inc.

Profitability

Table 2 provides the net margins, return on equity and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Regeneron Pharmaceuticals Inc. 36.36% 32.2% 23.4%
Infinity Pharmaceuticals Inc. -50.79% -20.8% -18.2%

Volatility & Risk

A 1.2 beta means Regeneron Pharmaceuticals Inc.’s volatility is 20.00% more than Standard & Poor’s 500’s volatility. Infinity Pharmaceuticals Inc. on the other hand, has 2.22 beta which makes it 122.00% more volatile compared to Standard & Poor’s 500.

Liquidity

Regeneron Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 4.5 and 3.9 respectively. The Current Ratio and Quick Ratio of its competitor Infinity Pharmaceuticals Inc. are 10.7 and 10.7 respectively. Infinity Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Regeneron Pharmaceuticals Inc.

Analyst Ratings

The Recommendations and Ratings for Regeneron Pharmaceuticals Inc. and Infinity Pharmaceuticals Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Regeneron Pharmaceuticals Inc. 0 3 2 2.40
Infinity Pharmaceuticals Inc. 1 1 1 2.33

Regeneron Pharmaceuticals Inc.’s average price target is $452, while its potential upside is 20.24%. On the other hand, Infinity Pharmaceuticals Inc.’s potential upside is 84.62% and its average price target is $3. The information presented earlier suggests that Infinity Pharmaceuticals Inc. looks more robust than Regeneron Pharmaceuticals Inc. as far as analyst opinion.

Insider & Institutional Ownership

The shares of both Regeneron Pharmaceuticals Inc. and Infinity Pharmaceuticals Inc. are owned by institutional investors at 72.7% and 54.9% respectively. Insiders owned 0.9% of Regeneron Pharmaceuticals Inc. shares. Competitively, Infinity Pharmaceuticals Inc. has 1.1% of it’s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Regeneron Pharmaceuticals Inc. 3.2% 1.06% 19.3% 6.69% 34.82% 16.15%
Infinity Pharmaceuticals Inc. -3.03% 32.23% 16.79% -21.57% -16.67% 35.59%

For the past year Regeneron Pharmaceuticals Inc. has weaker performance than Infinity Pharmaceuticals Inc.

Summary

Regeneron Pharmaceuticals Inc. beats Infinity Pharmaceuticals Inc. on 13 of the 15 factors.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrenÂ’s. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor. It also has collaboration agreements with Intellia Therapeutics, Inc. to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development; and the U.S. Department of Health and Human Services to develop treatments combating infectious diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. Its lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma) is in Phase 1 clinical study. The company has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.